To evaluate the efficacy and safety of enzalutamide for metastatic castration-resistant prostate cancer, including the optimal sequencing with abiraterone and/or chemotherapy, the clinical records of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in all 7 public oncology centers in Hong Kong between August 2015 and October 2017 were studied. Survival outcomes, prostate-specific antigen response, and the risk of fatigue were analyzed by line of treatment. Background: The present study retrospectively evaluated the efficacy and safety of enzalutamide in different lines of metastatic castration-resistant prostate cancer (mCRPC) treatment in a real-world setting. Patients and Methods: The clinical records of patients with mCRPC treated with enzalutamide between August 2015 and October 2017 were retrieved from all 7 public oncology centers in Hong Kong and reviewed. The primary endpoint was progression-free survival (PFS) in first (1L), second (2L), and third or fourth lines (3L or 4L) of CRPC treatment. Secondary endpoints included overall survival (OS), prostate-specific antigen (PSA) response, and tolerance. Results: Among a total of 117 patients (median age of 73 years [range, 52-90 years]), 34 (29.1%), 57 (48.7%), and 26 (19.3%) patients had enzalutamide as their 1L (chemo-naive), 2L (postdocetaxel or -abiraterone), and 3L or above treatment options. The overall PSA response rates were 43.6%, and were 73.5%, 35.1%, and 19.2% for 1L, 2L, and 3L or 4L treatment, respectively. PFS and OS were significantly associated with the line of treatment in the univariate survival analysis (1L/2L/3L and 4L; PFS, 7.1/3.9/2.2 months; OS, not reached/15.8/7.4 months; both P ¼ .0002) but not in the multivariate analysis. The observed incidence of any fatigue (grade 1 or 2, 54.7%; grade 3 or 4, 9.4%) was much higher than reported in the AFFIRM (A Study Evaluating the Efficacy and Safety of the Investigational Drug MDV3100 [ClinicalTrials. in both univariate and multivariate analyses). Conclusion: In the real-life setting, there was a higher incidence of enzalutamide-related fatigue than reported in the trials. Earlier lines of enzalutamide treatment were associated with longer PFS and OS, more frequent PSA response, and less fatigue.
Introduction
The efficacy, safety, and associated quality of life measures of enzalutamide, an androgen receptor (AR)-signaling pathway inhibitor, for metastatic castration-resistant prostate cancer (mCRPC) , with a resulting hazard ratio (HR) of 0.63 (95% CI, 0.53-0.75; P < .001). The PREVAIL trial (n ¼ 1717) evaluated enzalutamide versus placebo in chemotherapy-naive patients, with radiographic progression-free survival (rPFS) and OS as co-primary endpoints. The resulting HR for enzalutamide versus placebo for rPFS was 0.19 (95% CI, 0.15-0.23; P < .001) and for OS was 0.71 (95% CI, 0.60-0.84; P < .001). Follow-up studies and sub-analyses of these trials have produced consistent, beneficial results, including favorable rPFS and OS in chemotherapy-naive patients stratified by disease location and extent, 4 in patients ! 75 years of age, 5 and in Asian populations. [6] [7] [8] [9] Delayed median time to first skeletal-related event was shown in both chemotherapy-experienced 10 and chemotherapy-naive 11 patients. Reductions across the full range of Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores (P < .001) 12 and delayed health-related quality of life deterioration in chemotherapy-naive patients 13 were reported.
In recent developments, research studies have focused on the optimal sequencing of enzalutamide therapy, with regard to both chemotherapy (such as docetaxel) and to another AR-signaling pathway inhibitor, abiraterone, and the potential for crossresistance among them. It is noteworthy that authors have commented on the lack of head-to-head comparisons of the various sequencing possibilities, 14 including a direct comparison of enzalutamide versus abiraterone. 15 Although indirect comparisons 16 and retrospective data 17, 18 have shown better efficacy of enzalutamide versus abiraterone in prostate-specific antigen (PSA) response and PFS measurements, most retrospective studies also found that the sequencing of abiraterone-enzalutamide appears to be more favorable than enzalutamide-abiraterone in terms of combined PSA-PFS. 18, 19 Consequently, researchers have also raised the question of whether resistance to enzalutamide also confers resistance to abiraterone, and/or vice-versa, 18,20 the answer to which might also affect the choice of AR-signaling inhibitor versus chemotherapy when first-line enzalutamide or abiraterone has already been used. 21 A second set of questions surrounding enzalutamide therapy concerns the occurrence of fatigue, a potential treatment-related toxicity. Fatigue is one of the most concerned and most common side effects reported in the studies, although it is noteworthy that in both the AFFIRM and PREVAIL trials, fatigue occurred quite commonly in both the enzalutamide and placebo groups (any grade fatigue, 34% vs. 29% in AFFIRM and 36% vs. 26% in PREVAIL, with similarly small proportions of grade ! 3 fatigue, 6% vs. 7% in AFFIRM and 2% vs. 2% in PREVAIL). 1, 2, 22 Meanwhile, a prospective observation study (n ¼ 507) has reported a slightly higher percentage (39.1%) of all-grade fatigue than that in the trials. 23 A more detailed study on the occurrence of fatigue in enzalutamidetreated patients may provide insights for minimizing the incidence. The present study examined retrospectively the effect of the line of treatment on the efficacy and safety of enzalutamide in a realworld public clinic setting in Hong Kong. The study also aimed to shed light on the questions surrounding the optimization of treatment sequencing and minimization of the risk of fatigue.
Patients and Methods
The clinical records of all patients with mCRPC who were treated with enzalutamide between August 1, 2015 and October 31, 2017 were retrieved from all 7 public oncology centers in Hong Kong, reviewed, and analyzed. Data collected included demographics, treatment details, responses, and toxicities. The patients were treated with enzalutamide 160 mg daily until disease progression, death, or unacceptable toxicity, at the discretion of the physician. The treatment details are highlighted in Supplemental Table 1 (in the online version).
The primary endpoint was PFS in first-(1L), second-(2L), and third-or fourth-line (3L or 4L) of treatment. 1L enzalutamide treatment was defined as enzalutamide treatment to patients who were diagnosed with mCRPC and had not received chemotherapy (which was previously the standard of care for mCRPC) or abiraterone. 2L enzalutamide treatment was defined as enzalutamide treatment to patients after either chemotherapy or abiraterone. Patients were said to have received 3L or 4L enzalutamide if they previously received 2 or more of docetaxel, abiraterone, cabazitaxel, and/or radium-223. Secondary endpoints included OS and PSA response (decline ! 50%). Tolerance and safety measurements including fatigue and seizure were also assessed. The definitions of clinical, biochemical, and radiologic progressive disease followed As fatigue is arguably the most concerned side effect for enzalutamide, its severity was regularly assessed by the physicians on purpose using the CTCAE criteria. Statistical analyses were performed using IBM SPSS Statistics version 24. Cox regression survival analysis was used to assess PFS and OS. Variables included in the univariate and multivariate analyses were PSA response, Eastern Cooperative Oncology Group (ECOG) performance status, age, PSA flare, enzalutamide treatment beyond progressive disease, pre-enzalutamide alkaline phosphatase (ALP) level, pre-enzalutamide hemoglobin level, line of enzalutamide treatment, time to CRPC, pre-enzalutamide PSA level, Gleason score, presence of visceral metastasis, presence of ! 4 bone metastases, post-enzalutamide therapy(-ies) that was potentially life-prolonging, and symptomatic disease. Each variable was evaluated first by univariate analysis against PFS and OS, before being evaluated together in the multivariate analysis. P values .05 were considered significant. The HR and corresponding 95% CI were calculated.
The study was approved by the institutional review board of the authors' institution (Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee/Ref no: CRE-2017.461). Permission to access the medical records through the inter-hospital computer network was also granted by the aforementioned review board. Although the principles of the Helsinki Declaration were followed, informed consent was exempted by the review board as most of the patients in this study were deceased when the data were collected. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request and with permission of the institution(s) from which the data were obtained.
Results
A total of 117 patients were included in the analysis, with a median age of 73 years (range, 52-90 years) and a median follow-up time of 7.8 months (range, 0.1-24.1 months) ( Table 1) . At the start of enzalutamide treatment, most (76.1%) patients had an ECOG performance status of 0 to 1, with a median PSA at 82.7 mg/L (range, 1.3-10, 781 mg/L). Visceral (ie, liver and/or lung) metastases were present in 20.6%, 29.8%, and 50% of patients on 1L, 2L, and 3L or 4L enzalutamide, respectively.
The results of the Cox regression survival analysis for PFS and OS according to the line of treatment are illustrated in Figure 1 , revealing that both measures were significantly associated with the line of treatment (both P ¼ .0002). For 1L, 2L, and 3L or 4L Table 1 Continued
Median time from start of ADT to CRPC, mos (range) In the overall population studied, the presence of a PSA response was significantly associated with favorable PFS (HR, 0.29; P < .0001) as well as OS (HR, 0.19; P < .0001) ( Table 2) . Table 3 shows the results of the univariate and multivariate analyses of the evaluated variables. PFS and OS were significantly associated with the line of treatment in the univariate survival analysis but not in the multivariate analysis. In multivariate analysis, PFS was significantly associated only with PSA response (P < 
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and ALP level before enzalutamide treatment (P ¼ .01), whereas OS was variously significantly associated with PSA response (P < .0001), ALP level before enzalutamide treatment (P ¼ .045), PSA flare (P ¼ .02), time to CRPC (P ¼ .04), and postenzalutamide treatment (P < .0001). Adverse events are summarized in Table 4 . The most common grade 1 or 2 adverse events were fatigue (54.7%), hypertension (17.1%), arthralgia (5.1%), and hot flashes (5.1%). Grade 3 or 4 adverse events were fatigue (9.4%), hypertension (6%), elevated alanine aminotransferase level (< 1%), and cardiac disorder (< 1%). In the univariate as well as the multivariate analyses that included ECOG performance status among the variables, grade ! 2 fatigue was significantly associated with 3L or 4L treatment (both P ¼ .01). A more detailed analysis (Table 5) showed that fatigue was not significantly associated with age or the presence of comorbidities including diabetes, hypertension, and ischemic heart disease. Fatigue was associated with the duration of enzalutamide treatment only on univariate but not on multivariate analysis, and only marginally associated with ECOG performance status (P ¼ .15 on univariate analysis). No incidence of seizure was found.
Discussion
Significantly longer PFS and OS, more frequent PSA response, and less fatigue are observed with earlier lines of enzalutamide in the real-life setting. In comparison to our 19% PSA response and PFS of 2.2 months (95% CI, 1.7-4.0 months) for 3L or 4L enzalutamide, Badraising et al 24 reported an even more favorable PSA response rate of 23% and PFS of 12.1 weeks (95% CI, 9.9-14.0 weeks) for 4L or fifth-line enzalutamide. Also, our results as mentioned concerning the line of treatment are consistent with those for the other AR-signaling pathway inhibitor, abiraterone, for Chinese populations. 25, 26 With regard to the efficacy of enzalutamide treatment in patients with prior abiraterone and chemotherapy, a study by Azad et al 27 showed no significant difference in terms of OS and PSA response for the chemotherapy-naive abirateroneenzalutamide treatment versus chemotherapy-experienced abirateroneenzalutamide treatment. Their finding is somehow distinct from the general intuitive assumption, as well as our result, that enzalutamide is less efficacious in later lines of treatments. 14 Nonetheless, results of our current study, together with previous reports of diminishing and modest activities with later lines of enzalutamide after prior therapies, suggest that cross-resistance probably exists between chemotherapy drugs and AR-signaling pathway inhibitors, as well as AR-signaling pathway inhibitors per se. 21 Most of our patients who received enzalutamide as 2L treatment received 1L abiraterone (59.1%) and achieved a satisfactory PSA response rate of 29.5%, which is largely consistent with that reported for postabiraterone enzalutamide treatment in the literature (ie, in the range of 27%, 28 30%, 29 and 37% 30 ). This suggests that the sequence of abiraterone-enzalutamide treatment may be preferred over enzalutamideabiraterone, which is associated with a PSA response rate of only w10% to 2L abiraterone according to reports. 16, 18 Studies have also reported an overall better combined PFS for abiraterone-enzalutamide treatment versus enzalutamide-abiraterone treatment. 18, 19, 30 In terms of other predictors of treatment outcomes, consistent with previous studies, 25 ,31 a longer prior response to androgen deprivation therapy (reflected by the longer time to CRPC) was associated with better OS (P ¼ .04). As well, ALP level before Table 4 Most Common and Specific Adverse Events Toxicity 
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Clinical Genitourinary Cancer October 2018 -409 enzalutamide treatment (as cut off by the baseline median of > 135 IU/L) was a strong predictor of PFS (HR, 1.81; 95% CI, 1.14-2.88; P ¼ .02) and OS (HR, 9.82; 95% CI, 1.05-92.15; P ¼ .045). The presence of a PSA response was a major predictor of favorable PFS (HR, 0.29; P < .0001) as well as OS (HR, 0.19; P < .0001) ( Table 2 ). This finding could explain our result that the superior PFS and OS in the 1L setting may be related to the higher PSA response that could be achieved with the earlier use of enzalutamide. Future studies are warranted to evaluate the intensification or combination of enzalutamide with other treatments to enhance PSA response and the ultimate survival outcome.
Although considering that later lines of treatment would likely be associated with more advanced disease stages with poorer general conditions and tolerance to treatments (as our results showed), and the possible cross-resistance between enzalutamide, abiraterone, and chemotherapy (as in the above-discussed literature), the earlier use of enzalutamide may be favorable in terms of tolerability and survival outcome. Nonetheless, the optimal sequencing of treatments in mCRPC remains uncertain, as a sequence that starts with early enzalutamide may not be better than one that incorporates enzalutamide in later lines. Further studies addressing the sequencing are eagerly awaited.
To our surprise, a PSA flare was associated with worsened PFS and OS outcomes (Table 3) , contrary to previous reports in the literature that it is neutral. [32] [33] [34] At this moment, the exact mechanism of the PSA phenomenon and its implications for the ultimate survival outcome remain unknown. Hence, an early withdrawal of treatment while encountering such transient PSA elevation is not advocated. Interestingly, the observed incidence of any fatigue (grade 1 or 2, 54.7%; grade 3 or 4, 9.4%) was much higher than those reported in the AFFIRM (any grade, 34%) and PREVAIL (any grade, 36%) trials. This was consistently observed even for our chemotherapynaive patients (grade 1 or 2, 59.6%; grade 3 or 4, 7.0%), suggesting that fatigue might be more common in the real-world clinical setting than in the trial setting. A post hoc analysis of the Korean, Japanese, and Singaporean patients from the PREVAIL study indicated a lower incidence of fatigue of any grade among East Asians (n ¼ 139) versus the overall population (n ¼ 1715): 20.5% (enzalutamide arm) and 6.7% (placebo arm) versus 35.6% (enzalutamide) and 25.8% (placebo). 9 Contrary to our present finding, this post hoc analysis suggests that Asian ethnicity would contribute to less reports on fatigue. The difference in the rates of fatigue between our real-life data and the pivotal trials could in one way be attributed to the dissimilarity in patients' baseline characteristics (eg, patients with highly symptomatic disease were excluded from the PREVAIL study 2 but included in the current analysis). Incongruence between real-world clinical results and those reported by trials is common. 35 Our tentatively aggressive cohort with high baseline PSA levels and Gleason scores might explain the observed relatively large proportion of patients with visceral diseases (see Results). Another explanation could be that the incidence of fatigue in the trials were self-reported (with patient questionnaires), whereas in our study, it was physician-recorded. Thus, it might have been that physicians were more likely to report fatigue based on clinical observation, even for a short duration of fatigue, or related symptoms (details on the kinetics and duration of fatigue were not available in our data). It is also noteworthy that OS and PFS in the 3L and 4L setting might not be as reliable an indicator of enzalutamide treatment outcome as in earlier lines, because treatment modalities would have been more limited, and patients would generally have had worsened First and Later Lines of Enzalutamide for mCRPC baseline characteristics. In general, patients receiving later lines of treatment may have worsening bodily conditions and disease statuses that may affect enzalutamide tolerance, which might explain the AFFIRM versus PREVAIL results in which fatigue occurred more often in patients who were chemotherapy-experienced than those who were chemotherapy-naive. Interestingly , Table 4 also shows that, among those receiving 2L enzalutamide in our study population, fatigue was more commonly observed in postabiraterone (grade 1-2, 59.1%; grade 3-4, 9.1%) than postdocetaxel patients (grade 1-2, 47.1%; grade 3-4, 0%). This was possibly related to the long-term concurrent steroid use with abiraterone therapy and the usually short interval between abiraterone and enzalutamide treatments, suggesting that enzalutamide may be better tolerated after chemotherapy than after abiraterone. The present study was limited by the typical shortcomings of retrospective studies. First, there was an arguably heterogenous population without clear exclusion criteria, although all of the patients included in the analysis were from public oncology centers that followed essentially identical local institutional management procedures. Second, subjective judgment of clinical endpoints by different physicians existed, although the physicians were blinded in the sense that they were unaware of the study at the time of treatment and many of the endpoints included were measurable. Furthermore, the assessment of PFS might have been affected by variation in follow-up policies among the participating oncology centers. However, we believe that our reported OS was measured accurately. Finally, there is a plan for a follow-up study of this cohort as admittedly the current follow-up time may have been inadequate for the collection of more mature data. Nevertheless, we trust that the present study reflects to a good extent a "realworld" picture of clinical efficacy and safety of enzalutamide treatment, including insights for optimizing its efficacy and tolerance.
Conclusion
In this real-world study, there was a higher incidence of fatigue than reported in the trials. Longer PFS and OS, more frequent PSA response, and less fatigue was observed in patients with mCRPC with the earlier use of enzalutamide. A further prospective study is mandatory for validating such a positive impact.
Clinical Practice Points
The efficacy, safety, and associated quality of life measures of enzalutamide, an AR-signaling pathway inhibitor, for mCRPC have been established by the randomized controlled trials. However, treatment sequencing with abiraterone and/or chemotherapy and the risk of fatigue deserved further study. The present retrospective study from Hong Kong (n ¼ 117) confirmed that earlier lines of enzalutamide treatment were associated with longer PFS and OS, more frequent PSA response, and less fatigue. The presence of a PSA response was the only variable associated with both favorable OS (HR, 0.19; P < .0001) and PFS (HR, 0.29; P < .001) in the multivariate analysis.
The observed incidence of any fatigue (grade 1 or 2, 54.7%; grade 3 or 4, 9.4%) was much higher than those reported in the AFFIRM and PREVAIL trials. Physicians should be vigilant in detecting and managing enzalutamide-associated fatigue in the real-life setting. Although considering that later lines of treatment would likely be associated with more advanced disease stages with poorer general conditions and tolerance to treatments, as well as the potential cross-resistance between enzalutamide, abiraterone, and chemotherapy, the earlier use of enzalutamide may nevertheless be favorable in terms of tolerability and survival outcome.
Presence of eventual PSA response, n (within group %) 6 (35. (17) 3 (8) 12 (21) 1 (7) 11 (25) 6 (23) Treatment interruption, n (%) 17 (14) 7 (20) 5 (8) 1 (7) 4 (9) 5 (19) Reasons for discontinuing enzalutamide, n (%) 
